VK2735 (Oral) - (VENTURE)

July 29, 2026: Viking Therapeutics, Inc. (NASDAQ: VKTX) reported 2Q26 financial results and provided pipeline updates focused on obesity.

VK2735 (dual GLP-1/GIP agonist), subcutaneous formulation: Phase 3 VANQUISH-1 (obesity) and VANQUISH-2 (obesity + type 2 diabetes) registration trials are fully enrolled and advancing. VANQUISH-1 enrolled ~4,500 patients (completed Nov 2025) and VANQUISH-2 enrolled ~1,000 patients (completed in 1Q26). Trials are randomized, double-blind, placebo-controlled, once-weekly dosing (7.5 mg, 12.5 mg, 17.5 mg, or placebo) for 78 weeks; primary endpoint is % change in body weight vs placebo at 78 weeks, with weight-loss threshold secondary/exploratory endpoints.

VK2735, oral tablet formulation: Phase 3 initiation is expected in 4Q26, following positive Phase 1/2 results (including Phase 2 VENTURE-oral top-line results and additional data presented at ECO in May 2026).

VK2735 maintenance dosing: Phase 1 dose-ranging maintenance regimen study (~180 adults with obesity; weekly induction then weekly/every-other-week/monthly maintenance) is ongoing; results are expected in 3Q26.

VK3019 (DACRA amylin/calcitonin receptor agonist): IND filed 1Q26; after IND clearance, a Phase 1 single-ascending-dose trial was initiated in 2Q26.

Financials/cash: Cash, cash equivalents and short-term investments were $502M as of June 30, 2026 (vs $706M at Dec 31, 2025); 2Q26 net loss was $128.0M. Conference call scheduled for 4:30 p.m. ET July 29, 2026.